BioWorld

Jan. 19, 2006

View Archived Issues

Cytokinetics Raising $33M For Clinic, Corporate Uses

Cytokinetics Inc. is raising $33 million through a stock sale to fund clinical development of its lead products, including a heart failure drug that recently started a Phase I trial. (BioWorld Today) Read More

Aphios Forms Amyxa To Focus On Influenza Drugs

Read More

Approval Of Orencia Behind BMS, Repligen CTLA4 Clash

Read More

Safety First: In Vitro Toxicology Firm CeeTox Offers Early Data

Read More

Other News To Note

Read More